These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

96 related articles for article (PubMed ID: 21351182)

  • 1. Paediatric post-marketing pharmacovigilance: comparison of the adverse event profile of vigabatrin prescribed to children and adults.
    Aurich-Barrera B; Wilton L; Brown D; Shakir S
    Pharmacoepidemiol Drug Saf; 2011 Jun; 20(6):608-18. PubMed ID: 21351182
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Paediatric postmarketing pharmacovigilance using prescription-event monitoring: comparison of the adverse event profiles of lamotrigine prescribed to children and adults in England.
    Aurich-Barrera B; Wilton L; Brown D; Shakir S
    Drug Saf; 2010 Sep; 33(9):751-63. PubMed ID: 20701408
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pediatric drug surveillance and the Food and Drug Administration's adverse event reporting system: an overview of reports, 2003-2007.
    Johann-Liang R; Wyeth J; Chen M; Cope JU
    Pharmacoepidemiol Drug Saf; 2009 Jan; 18(1):24-7. PubMed ID: 19009550
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety of gadobenate dimeglumine (MultiHance): Summary of findings from clinical studies and postmarketing surveillance.
    Shellock FG; Parker JR; Venetianer C; Pirovano G; Spinazzi A
    Invest Radiol; 2006 Jun; 41(6):500-9. PubMed ID: 16763468
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A modified prescription-event monitoring study to assess the introduction of Flixotide Evohaler into general practice in England: an example of pharmacovigilance planning and risk monitoring.
    Perrio MJ; Wilton LV; Shakir SA
    Pharmacoepidemiol Drug Saf; 2007 Sep; 16(9):969-78. PubMed ID: 17476703
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety profile of oxcarbazepine: results from a prescription-event monitoring study.
    Buggy Y; Layton D; Fogg C; Shakir SA
    Epilepsia; 2010 May; 51(5):818-29. PubMed ID: 20132298
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Visual impairment in children with epilepsy treated with vigabatrin.
    Gross-Tsur V; Banin E; Shahar E; Shalev RS; Lahat E
    Ann Neurol; 2000 Jul; 48(1):60-4. PubMed ID: 10894216
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The state of adverse event reporting and signal generation of dietary supplements in Korea.
    Park KS; Kwon O
    Regul Toxicol Pharmacol; 2010 Jun; 57(1):74-7. PubMed ID: 20074608
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Assessment of utilization and pharmacovigilance based on spontaneous adverse event reporting of gadopentetate dimeglumine as a magnetic resonance contrast agent after 45 million administrations and 15 years of clinical use.
    Knopp MV; Balzer T; Esser M; Kashanian FK; Paul P; Niendorf HP
    Invest Radiol; 2006 Jun; 41(6):491-9. PubMed ID: 16763467
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The safety and effectiveness of newer antiepileptics: a comparative postmarketing cohort study.
    Acharya NV; Pickering RM; Wilton LW; Shakir SA
    J Clin Pharmacol; 2005 Apr; 45(4):385-93. PubMed ID: 15778419
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Italian post-marketing surveillance for adverse event reports after MF59-adjuvanted H1N1v vaccination.
    Parretta E; Ianniello B; Ferrazin F; Rossi F; Capuano A
    Vaccine; 2011 May; 29(20):3708-13. PubMed ID: 21406267
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Study of visual field and vigabatrin treatment in children].
    Pelosse B; Momtchilova M; Roubergue A; Doummar D; Billette de Villemeur T; Laroche L
    J Fr Ophtalmol; 2001 Dec; 24(10):1075-80. PubMed ID: 11913238
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety profile of orlistat: results of a prescription-event monitoring study.
    Acharya NV; Wilton LV; Shakir SA
    Int J Obes (Lond); 2006 Nov; 30(11):1645-52. PubMed ID: 16552401
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Paediatric adverse drug reaction reporting: understanding and future directions.
    Carleton BC; Smith MA; Gelin MN; Heathcote SC
    Can J Clin Pharmacol; 2007; 14(1):e45-57. PubMed ID: 17297195
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A postmarketing surveillance study of gabapentin as add-on therapy for 3,100 patients in England.
    Wilton LV; Shakir S
    Epilepsia; 2002 Sep; 43(9):983-92. PubMed ID: 12199723
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Patient reporting of adverse drug reactions: useful information for pain management?
    Jarernsiripornkul N; Krska J; Richards RM; Capps PA
    Eur J Pain; 2003; 7(3):219-24. PubMed ID: 12725844
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Safety of zafirlukast: results of a postmarketing surveillance study on 7976 patients in England.
    Twaites BR; Wilton LV; Shakir SA
    Drug Saf; 2007; 30(5):419-29. PubMed ID: 17472420
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Applying quantitative methods for detecting new drug safety signals in pharmacovigilance national database.
    Shalviri G; Mohammad K; Majdzadeh R; Gholami K
    Pharmacoepidemiol Drug Saf; 2007 Oct; 16(10):1136-40. PubMed ID: 17705214
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Adverse drug reactions in children in Camagüey Province, Cuba.
    Arencibia ZB; Sotomayor DN; Mollinedo NC; Choonara I; Manzano EF; Leyva AL
    Arch Dis Child; 2010 Jun; 95(6):474-7. PubMed ID: 20501541
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Paediatric adverse drug reactions reported in Sweden from 1987 to 2001.
    Kimland E; Rane A; Ufer M; Panagiotidis G
    Pharmacoepidemiol Drug Saf; 2005 Jul; 14(7):493-9. PubMed ID: 15918163
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.